The Technical AnalystExchange: NASDAQ Sector: Healthcare Industry: Medical Devices
enVVeno Medical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.14% $4.63
America/New_York / 19 apr 2024 @ 14:23
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 61.66 mill |
| EPS: | -1.910 |
| P/E: | -2.42 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 13.32 mill |
| Avg Daily Volume: | 0.131 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.42 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -2.42 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.180 (-96.11%) $-4.45 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.22 - 5.04 ( +/- 8.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-13 | Alavi Hamed | Sell | 8 334 | Stock Options |
| 2024-03-13 | Alavi Hamed | Buy | 8 334 | Common Stock |
| 2024-03-13 | Alavi Hamed | Sell | 8 334 | Common Stock |
| 2023-12-05 | Glynn Craig | Buy | 75 000 | Stock Options |
| 2023-12-05 | Jenusaitis Matthew | Buy | 13 856 | Stock Options |
| INSIDER POWER |
|---|
| 43.18 |
| Last 98 transactions |
| Buy: 6 344 915 | Sell: 2 475 147 |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.63 (-3.14% ) |
| Volume | 0.0617 mill |
| Avg. Vol. | 0.131 mill |
| % of Avg. Vol | 47.06 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NVNO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.